TCF7L2 regulates pancreatic β-cell function through PI3K/AKT signal pathway

BackgroundTranscription factor 7-like 2 (TCF7L2), which previously known as TCF-4, is a major form of transcription factor involved in the downstream WNT signaling and exhibits the strongest association to diabetes susceptibility. Although we still do not know mechanistically how TCF7L2 exerts its physiological functions on pancreatic endocrine cells, it had been suggested that TCF7L2 may directly affect beta-cell function by regulating the activation ofPI3K/AKT signaling pathway.MethodsMIN6 cells were transfected with TCF7L2 knockdown virus or lenti-TCF7L2 virus for 48h to evaluate the contribution of TCF7L2 to the PI3K/AKT signaling pathway and pancreatic beta-cell function. This was confirmed by measuringthe expression of PI3K p85 and p-Akt by western blotting and insulin secretion by enzyme-linked immunosorbent assay (ELISA), respectively. Chromatin immunoprecipitation (ChIP) and polymerase chain reaction (PCR) experiments were performed to explore the genomic distribution of TCF7L2-binding sites in the promoter of PIK3R1, the affinity between which was analyzed by the luciferase reporter assay.ResultsIn the present study, we strikingly identified that TCF7L2 could profoundly inhibit the expression of PIK3R1 gene and its encoding protein PI3K p85, which then could lead to the activation of PI3K/AKT signaling and stimulate insulin secretion in pancreatic beta-cells. However, the integrity and stability of evolutionarilyconserved TCF7L2-binding motif plays a very crucial role in the binding events between transcription factor TCF7L2 and its candidate target genes. We also found that the affinity of TCF7L2 to the promoter region of PIK3R1 alters upon the specific binding sites, which further provides statistical validation to the necessity of TCF7L2-binding motif.ConclusionsThis study demonstrated that TCF7L2 is closely bound to the specific binding regions of PIK3R1 promoter and prominently controls the transcription of its encoding protein p85, which further affects the activation ofPI3K/AKT signaling pathway and insulin secretion.